arrow
P

Philip R. Dormitzer

Pfizer
H指数:61
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development

建立用于巨细胞病毒疫苗开发的婴幼儿自然传播模型

2026-04-010
PRE
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

作者更正: BNT162b2疫苗在人类中诱导中和抗体和多特异性T细胞

Nature
IF48.5
2025-07-160
PRE
Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa

呼吸道合胞病毒疾病与血清学在孕期及婴儿期于美国和南非的动态变化

2025-07-010
OAAI
Rational design of a highly immunogenic prefusion- stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine
2023-04-2634
PRE
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

在健康老年人中使用和不使用佐剂的呼吸道合胞病毒融合前F疫苗的1/2期研究

2022-05-1128
OAAI
Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses
2022-04-1211
OA
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics

基于RNA的疗法的mRNA结构,稳定性和翻译的组合优化

2022-03-22141
OAAI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
2022-01-06432
OAAI
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

呼吸道合胞病毒前F疫苗与灭活流感疫苗在成人中的免疫原性,安全性和耐受性的1/2期随机研究

2021-12-2152
OAAI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
2021-11-04972
OAAI
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
2021-10-21276
OAAI
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine

与破伤风,白喉和无细胞百日咳疫苗共同施用时,呼吸道合胞病毒融合前F疫苗的安全性和免疫原性

2021-10-1228
OAAI